Global Ganja Report

Cannabis has become a global industry, but obviously it is still limited by legal restrictions—and the fact that these increasingly vary from country to country further complicates things. Where is commercial cannabis going and where is it coming from? And how is this likely to change as the international atmosphere further liberalizes?

After much speculation that the US Drug Enforcement Agency (DEA) would reschedule cannabis this summer, the agency on Aug. 11 dashed petitioners' hopes, rejecting their request to remove its classification as a Schedule I dangerous drug. The DEA denied two separate requests by former state governors to re-classify cannabis as a Schedule II drug or lower. The agency stated (PDF) that the Department of Health and Human Services (HHS) has "concluded that marijuana has high potential for abuse, has no accepted medical use in the United States, and lacks an acceptable level of safety for use even under medical supervision." Tthe DEA did propose a new policy that would allow universities to apply to grow cannabis for research. Until now, the University of Mississippi had a monopoly on cultivation for study. (Jurist)